GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Eloxx Pharmaceuticals ELOX · USD

Health Care · US listing · 🇺🇸 United States

Compare

13.51

+8.60%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2022

Revenue

—

FY2014FY2022

Net income

−$36.1m

FY2014FY2022

Free cash flow

−$31.9m

FY2014FY2022

Shareholders' equity

−$10.7m

FY2014FY2022

Income statement

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue———————$80,000$80,000
Research and development$23.7m$45.6m$14.6m$25.8m$20.5m$16.4m$730,000$2.2m$4.6m
Operating income−$34.4m−$66.0m−$29.4m−$50.6m−$47.0m−$20.4m−$4.7m−$5.4m−$7.7m
Net income−$36.1m−$66.7m−$34.6m−$50.9m−$47.2m−$23.6m−$6.2m−$8.4m−$18.9m
Diluted earnings per share-16.65-38.15-0.86-1.34-1.45-4.75-5.34-8.28-26.25

Balance sheet

At each fiscal year end

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$21.1m$45.1m$26.5m$59.0m$50.7m$24.8m$5.8m$9.2m$19.6m
Cash and short-term investments$19.2m$42.3m$24.7m$56.3m$48.6m$24.1m$30,000$810,000$3.3m
Total liabilities$31.8m$22.8m$16.3m$22.7m$7.8m$3.4m$5.0m$4.7m$7.3m
Debt$12.5m$12.0m$11.6m$14.8m——$410,000——
Shareholders' equity−$10.7m$22.4m$10.2m$36.2m$42.9m$21.4m$870,000$4.6m$12.2m
Shares outstanding2m2m40m38m32m5m1m1m1m

Cash flow

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations−$31.8m−$35.0m−$28.2m−$39.4m−$31.4m−$15.9m−$1.9m−$3.7m−$7.3m
Capital spending−$66,000−$89,000—−$40,000−$240,000−$240,000——−$260,000
Free cash flow−$31.9m−$35.1m−$28.2m−$39.4m−$31.6m−$16.2m−$1.9m−$3.7m−$7.6m

Latest quarters

By quarter end

Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022Mar 2022Dec 2021
Operating income−$3.6m−$4.1m−$5.5m−$6.0m−$7.1m−$10.3m−$11.0m−$11.6m
Net income−$3.6m−$4.3m−$6.2m−$6.3m−$7.5m−$10.6m−$11.6m−$12.1m
Diluted earnings per share-1.31-1.96-2.88-2.92-3.47-4.90-5.36-5.59
Total assets$6.0m$6.0m$7.2m$21.1m$26.9m$32.9m$43.6m$45.1m
Cash and short-term investments$4.8m$4.3m$4.9m$19.2m$24.6m$30.0m$39.8m$42.3m
Debt$2.6m$3.3m$4.0m$8.6m$9.9m$11.1m$12.1m$12.0m
Shareholders' equity−$20.0m−$18.6m−$16.3m−$10.7m−$5.0m$1.8m$11.7m$22.4m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-12.0%11.0%22.3%
Net income-10.8%8.8%17.8%

Valuation history

At each fiscal year end

FY2022FY2021FY2020
Price to earnings-0.0-0.0-6.0

Share price return

Finished calendar years

202520242023202220212020
Return0%-100%-47%-83%-84%-40%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 11-to-1 reverse split · 1 Jun 2026
  • 40-to-1 reverse split · 2 Dec 2022
  • 20-to-1 reverse split · 20 Dec 2017
  • 100-to-1 reverse split · 21 Oct 2013
  • 2-for-1 split · 25 Oct 1999
  • 3-to-1 reverse split · 22 Jan 1999

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.